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T
ype 2 diabetes is associated with impaired insu-
lin secretion. Both 1st- and 2nd-phase insulin
secretion are reduced, but the effect is particu-
larly pronounced for the 1st phase. The pro-
cesses culminating in impaired insulin secretion are not
fully understood, but both genetic and environmental
factors are thought to play a role. Over the past 2 years,
genome-wide association scans have transformed the ge-
netic landscape of type 2 diabetes susceptibility, with the
current gene count close to 20 (1). A couple of common
themes have emerged from these studies. First, the major-
ity of the genes identiﬁed thus far seem to affect diabetes
susceptibility through -cell dysfunction (2). Second, the
risk alleles tend to be common in the population, but their
effect on diabetes risk is relatively small (3,4).
TCF7L2, the susceptibility gene with the largest effect
on disease susceptibility discovered to date, was iden-
tiﬁed pre–genome-wide association by Grant et al. in
2006, with rapid replication of its consequence on
diabetes susceptibility in multiple populations (5–9).
TCF7L2 was a positional candidate gene that mapped to
a region of genetic linkage to type 2 diabetes in the
Icelandic population on chromosome 10. However, the
identiﬁed TCF7L2 risk allele, which was present in
28% of control subjects and 36% of type 2 diabetic
individuals, could not explain this linkage, so the ﬁnding
was actually serendipitous (5). The precise genetic
defect that causes the association of TCF7L2 with type
2 diabetes remains unclear. There is a large number of
highly correlated variants, none of which are obvious
functional candidates, that show association with dia-
betes (5). The most likely candidate is the single nucle-
otide polymorphism rs7903146, which shows the
strongest association with diabetes and resides in a
noncoding region with no obvious mutational mecha-
nism. It is clear, however, that the effect of the TCF7L2
risk allele is through a defect in insulin secretion (9).
There have been few studies investigating the role of
TCF7L2 on insulin secretion in isolated islets. Recently, a
study by Shu et al. (10) reported that silencing of TCF7L2
by siRNA resulted in strong suppression of insulin secre-
tion in human and mouse islets. Conversely, overexpres-
sion of TCF7L2 stimulated insulin secretion. Exactly how
TCF7L2 protein levels modulate insulin secretion was not
established in the study by Shu et al.
The normal regulation of insulin secretion from pan-
creatic -cells is well understood (Fig. 1A [11]). As
reported in this issue of Diabetes, da Silva Xavier et al.
(12) studied the effects of overexpression and knock-
down of TCF7L2 on -cell function using an impressive
battery of cell physiological techniques. They conﬁrm
that silencing of TCF7L2 exerts a strong inhibitory
effect on glucose-induced insulin secretion. By contrast,
insulin secretion triggered by high extracellular K
 was
not affected. Unlike what was seen in the study of Shu et
al., overexpression of TCF7L2 did not affect insulin
secretion. The inhibition of glucose-stimulated insulin
secretion produced by TCF7L2 silencing was not asso-
ciated with any lowering of [Ca
2]i; if anything, the
responses to glucose were larger in cells lacking
TCF7L2. This suggests that glucose sensing in the -cell
was unaffected.
Given these functional data, the inhibitory action of
TCF7L2 gene silencing on glucose-induced insulin secre-
tion seems paradoxical insofar as no part of the -cell
stimulus-secretion coupling was perturbed in a way that
would suppress insulin release. This might indicate that
the distal events involved in the fusion of the secretory
granules might be involved (although the ﬁnding that
insulin secretion elicited by high K
 was unaffected seem-
ingly militates against this notion). This would be consis-
tent with the observation that TCF7L2 silencing affected
the levels of the exocytotic proteins syntaxin-1 and
munc18-1. It is unlikely, however, that reduced expression
of munc18-1 alone is responsible for the observed defect
because knockdown of this protein in -cells inhibited
both glucose- and high-K
–induced secretion and inter-
fered with granule docking (13). The authors further
investigated the secretory defect by capacitance measure-
ments of the increase in cell surface area resulting from
the addition of the granule membranes to the plasma
membrane. When the -cells were depolarized for 2.5 s,
the inhibitory effect was limited to 40%. However, re-
sponses to depolarizations as short as 0.2 s were reduced
by 80%. This is signiﬁcant because the -cell action poten-
tial is 100 ms (14). The observation that the inhibitory
effect of TCF7L2 silencing was particularly strong for the
brief depolarizations suggests that TCF7L2 somehow af-
fects the distribution of voltage-gated Ca
2 channels (Fig.
1B). There is evidence that interference with the associa-
tion of Ca
2 channels and secretory granules principally
affects exocytosis triggered by brief stimuli in -cells (15).
This would be in agreement with the observations that
insulin secretion is evoked by high extracellular K
. The
latter condition produces a global elevation of [Ca
2]i and
triggers exocytosis of all release-competent granules at the
plasma membrane regardless of whether they are associ-
ated with the voltage-gated Ca
2 channels (Fig. 1C).
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COMMENTARY
800 DIABETES, VOL. 58, APRIL 2009Although it remains to be determined exactly how a
reduction of TCF7L2 inhibits insulin secretion, the
report of da Silva Xavier et al. is signiﬁcant because it is
one of the ﬁrst detailed studies of the mechanisms by
which the diabetes gene affects insulin secretion. The
fact that the most strongly associated diabetes suscep-
tibility variants in TCF7L2 are all in the noncoding
region suggests that they affect disease susceptibility by
inﬂuencing the expression levels (16). The ﬁnding that
silencing TCF7L2 is associated with strong inhibition of
insulin secretion whereas overexpression, if anything,
stimulates insulin secretion makes it tempting to spec-
ulate that diabetes results from reduced TCF7L2 ex-
pression. It is therefore unexpected that the only study
thus far that has compared TCF7L2 expression in
nondiabetic and diabetic human islets found that type 2
diabetes is associated with a ﬁvefold increase in
TCF7L2 mRNA levels (17). Clearly, the latter observa-
tion must be conﬁrmed. Finally, we echo the authors’
statement that the changes in TCF7L2 expression used
in this study (and an earlier study) are “likely to
considerably exceed those observed in carriers of the
at-risk T-allele of TCF7L2. Future studies will be re-
quired to assess how more subtle variations in TCF7L2
level impact on -cell function.... ”I naddition, studies
investigating the temporal and speciﬁc TCF7L2 isoform
expression proﬁles in human islets are required to fully
elucidate the role of this key transcription factor in islet
development and function.
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